{"anticipatedPostingDate":"2026-12","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years 4 months","title":"Percentage of Participants With Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies","type":"SECONDARY"}